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INTRODUCTION
Vascular permeability characterises the capacity of the blood vessel wall to regulate the movement of fluid, solutes and plasma proteins out of the vasculature and into the surrounding tissue. This process is fundamentally controlled by the vascular endothelial cells (ECs), which form a continuous cellular monolayer that lines the luminal surface of blood vessels and acts as a size-selective, semi-permeable barrier between the blood plasma and the extracellular space [47] .
The integrity of the vascular EC barrier is important for controlling normal physiological processes such as tissue fluid homeostasis but significant alterations in barrier integrity are associated with many inflammatory and pathological conditions, including allergic rhinitis, anaphylaxis, aberrant wound healing, cancer, edema, psoriasis and rheumatoid arthritis [19, 51] .
Various mediators are capable of increasing vascular permeability by generating changes in the adhesive properties of the inter-endothelial junctions. Compounds such as histamine,
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bradykinin, thrombin and vascular-endothelial growth factor (VEGF) are permeability-inducing agents, acting through different signaling pathways to cause disruption of the EC barrier [32] . In contrast, mediators such as the bioactive lipid sphingosine-1-phosphate (S1P) [5] , fibroblast growth factor [50] and angiopoietin-1 enhance the integrity of the EC barrier [59] . More importantly, these particular compounds play a fundamental role in regulating basal barrier integrity and are essential for protecting the EC barrier after exposure to injury or inflammatory conditions. The phospholipid S1P is a well-established pro-survival molecule and a key cell signaling mediator involved in a range of cellular processes, including cell trafficking, differentiation, angiogenesis and inflammation (as reviewed in [23, 43, 58, 60] ). S1P has a concentration in human plasma ranging from 200-400 nM [10, 82] and is secreted primarily from erythrocytes and activated platelets [33] although ECs, hepatocytes, neutrophils and mast cells can also contribute to the release of S1P [79] [80] [81] . A family of five G-protein coupled receptors (S1P [1] [2] [3] [4] [5] ) bind S1P to initiate functional changes in cell signaling [24, 64] . By signaling through EC expressed S1P 1 , S1P is able to robustly maintain the integrity of the EC barrier and this is well demonstrated by numerous studies [1, 5, 7, 11, 40, 46] . However, high levels of S1P can lead to signaling through S1P 2 or S1P 3 , which can lead to disruption of the EC barrier [36, 63] .
Synthesis of S1P occurs via phosphorylation of sphingosine by the intracellular sphingosine kinases SK-1 and SK-2 [74] . Despite their common function in catalysing the biosynthesis of S1P, SK-1 and SK-2 localise to both overlapping and distinct subcellular compartments [26, 30, 44, 57] , exhibit different developmental and adult expression patterns [39, 48] and are recognised to have both equivalent and alternative biological functions [26, 44, 73] . Whilst the role that S1P plays in maintaining EC barrier integrity is well established, the relationship between the two SK isoforms and EC barrier integrity is less defined. Previous work by our laboratory has demonstrated that siRNA knock-down of SK-1 reduced EC barrier integrity in vitro, which was supported by SK-1 knock-out mice (Sphk1 -/-) exhibiting higher
This article is protected by copyright. All rights reserved. levels of vascular leakage [37] . Other studies have also reported that SK-1 activity is important for maintaining EC barrier integrity and for restoring barrier function following challenge with inflammatory agents [13, 52, 75] . In contrast, there is little evidence describing any link between SK-2 activity and EC barrier integrity. A study by Maines et al showed that administration of the SK-2 inhibitor ABC294640 was able to limit VEGF-induced increase in vascular permeability in mice [45] , whilst in vivo studies in SK-2 knock-out (Sphk2 -/-) mice undergoing an anaphylactic challenge did not support this [52] .
In the current study, we specifically investigated the role of SK-2 in regulating EC barrier integrity and how it may complement SK-1. A high throughput in vitro cell impedance based assay was employed in combination with a range of pharmacological inhibitors to SK-1 and SK-2. Data from the in vitro assay suggested that inhibition of SK-2 activity was more detrimental to EC barrier integrity than inhibition of SK-1. In addition to the in vitro studies, we used an in vivo model of intravital microscopy to compare EC barrier integrity in the ear microvasculature of wild-type (WT), Sphk1 -/-and Sphk2 -/-mice. Measurement of a fluorescent tracer revealed that
Sphk1
-/-mice have a compromised EC barrier, whilst the Sphk2 -/-mice exhibited no difference in barrier integrity when compared to the WT mice. The novelty of these findings lies in the investigation of SK-2 functionality in the maintenance of basal EC barrier integrity, which was interrogated using both in vivo and in vitro methods. With our work also confirming a role for SK-1, these findings provide evidence to suggest that both SK isoforms could be potential therapeutic targets for conditions that exhibit aberrant vascular barrier function. Given the prevalence of conditions such as allergy, cancer and rheumatoid arthritis, wherein vascular integrity is compromised, such treatments could be of significant clinical relevance.
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METHODS

Reagents
Reagents were purchased from the following suppliers: histamine, histamine-1-receptor inhibitor [17, 56] .
Animals
WT, Sphk1 -/-and Sphk2 -/-mice were on a C57Bl/6 background were generously provided by Prof. Richard Proia (NIH) and have been described previously [6, 49] . Mice were housed under pathogen-free conditions at SA Pathology Animal Care Facility (South Australia, Australia).
Both male and female mice were used for the intravital microscopy and were aged between 8-12 weeks of age. All experimental procedures were approved by the Animal Ethics Committee of SA Pathology and conform to the guidelines established by the 'Australian Code of Practice for the Care and Use of Animals for Scientific Purposes'.
Cell culture
The collection of human umbilical cords for use in this study was given ethical clearance from 
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as previously described [38] . Briefly, HUVEC were cultured in M199 medium (Sigma-Aldrich) containing 20% fetal bovine serum (Life Technologies), 20 mM Hepes, 2 mM glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids (Cytosystems), 0.225% sodium bicarbonate, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco BRL, Paisley, Scotland). HUVEC were used at passage 2 or less for subsequent assays and were cultured in charcoal stripped fetal bovine serum, which depletes approximately 95% of the serum S1P [9] . Transformed human bone marrow ECs (TrHBMEC) were kindly supplied by Prof. Andrew Zannettino (SAHMRI, Adelaide, Australia) and have described previously [66] . The cells were cultured under the same conditions as described above for HUVEC, with the exception that the media was supplemented with heparin (Sigma-Aldrich) and endothelial growth factor (Corning, New York, USA) at 15 ng/µl.
In vitro EC barrier integrity assay
To assess HUVEC and TrHBMEC barrier integrity in vitro, we employed the xCELLigence RTCA DP Analyzer (ACEA Biosciences, San Diego, USA), which measures fluctuations in electrical impedance when a population of cells is grown in a specialised plate (E-Plate 16)[72].
The well bottom of an E-Plate 16 (5.0 mm diameter) contains a planar gold array of electrodes which cover 80% of the surface area and permit cell attachment with or without matrices where the sensor impedance of the plate prior to cell seeding is 17 Ω ± 5 Ω at a frequency of 10 kHz.
Twenty four hours after initial seeding, the wells were randomly assigned to control or treatment 
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Intravital microscopy
Intravital microscopy to measure in vivo barrier integrity of the mouse ear vasculature was performed as described previously [14] . Mice were sedated using an intra-peritoneal injection of a 10 mg/ml ketamine/xylazine mixture at a dosage of 1 μl per gram. The mouse ear was then placed over a raised platform and mounted under a glass coverslip in preparation for imaging.
Prior to imaging, the mouse was allowed to rest for 30 minutes to reduce any potential inflammation that may have resulted from the manual handling. To visualise the vasculature, 100
μl of 10 mg/ml FITC-dextran (150, 70 or 40 kDa) was injected intravenously via an intra-orbital injection. The mouse ear was then positioned under a 20x objective within a heated chamber of an LSM 710 two-photon microscope (Carl Zeiss, Jena, Germany). The FITC-Dextran was excited using a tuneable Mai Tai Ti:Sapphire multiphoton laser (Spectra-Physics, Santa Clara, USA) and external non-descanned detectors were used to capture the fluorescence signal. A stack of 3 images over a range of 10 μm was then acquired every 5 minutes over the course of 15 minutes. Image analysis was undertaken using a macro written for use within Image J [61] . As all images were in color, the green channel was split out and then a median filter with a radius of 2.0 pixels was employed to reduce noise. A fluorescence threshold was then manually applied by the user to the time zero image, with subsequent images in the series then using the threshold values from the time zero image. Image analysis then determined the percentage area covered by the threshold region. For analysis of average vessel diameter, measurements were taken from the
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time zero image of each mouse using Image J. Vessels were defined as small (less than 8 µm diameter), medium (8-13 µm diameter) or large (> 13 µm diameter). The number of vessels within each group was then counted and calculated as a proportion of the total number of vessels in that image.
Statistical analysis
Immediately prior to each independent EC barrier integrity assay experiment being conducted we 
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RESULTS
Histamine rapidly induces a decrease in HUVEC barrier integrity
The role of histamine in inducing EC permeability is well-established and as a consequence it was used in this study to establish the validity of measuring EC barrier integrity in vitro using the xCELLigence RTCA DP Analyzer. In the first instance, HUVEC were seeded into the gelatin- 
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μM) [70] 40 minutes prior to treatment with 12.5 μM histamine ( Figure 1C ). Pre-treatment with chlorpheniramine was able to completely abolish the fall in barrier integrity seen with histamine treatment alone. In addition, HUVEC were also pre-treated with the known histamine-2-receptor inhibitor cimetidine (10 μM) [70] , this had no effect on reducing histamine-induced loss of barrier integrity ( Figure 1D ). Quantified data from independent experiments using three different biological HUVEC donors showed via area under the curve (AUC) calculations that pretreatment with the H1R inhibitor (chlorpheniramine) significantly inhibited histamine-induced loss of barrier integrity ( Figure 1E ).
The SK-1 inhibitor PF543 has a modest effect on HUVEC barrier integrity
To investigate whether inhibition of SK-1 could disrupt basal EC barrier integrity in vitro, the commercially available SK-1-selective inhibitor PF543 was administered to HUVEC monolayers. PF543 was administered at concentrations of 10 nM, 25 nM, 50 nM and 100 nM ( 
The SK-2 inhibitor ABC294640 decreased HUVEC barrier integrity
Next we utilised a commercially available SK-2-selective inhibitor, ABC294640, in the in vitro HUVEC barrier integrity assay. Given that the K i for ABC294640 is 9.8 µM [17] , we administered the inhibitor at concentrations ranging from 5 μM to 40 μM. Whilst no effect was
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evident at 5 µM and 10 µM, the higher concentrations of 20 µM and 40 µM were able to induce a significant decrease in HUVEC barrier integrity ( Figure 3 ). Notably, treatment with 40 µM of ABC294640 resulted in a 73 ± 16% decrease in cell index readings within 15 minutes, which was the largest reduction seen with any of the inhibitors used in this study. However, it is possible that at a concentration of 40 µM, ABC294640 is slightly cytotoxic, as cell index readings do not return to baseline levels after 12 hours in culture (Supplementary Figure 2) . This effect may be attributed to the 0.4% methanol vehicle used for this compound as cytotoxicity was not evident at the lower concentrations of ABC294640 (Supplementary Figure 2) .
Combination of PF543 and ABC294640 enhances the decrease in HUVEC barrier integrity
In order to further establish whether simultaneous inhibition of both SK-1 and SK-2 can have a more potent impact on EC barrier integrity, a combination treatment of PF543 and ABC294640 was employed. Both inhibitors were used at their optimal concentration as derived from the previous experiments, with PF543 at 100 nM and ABC294640 at 20 µM. The ABC294640 concentration was chosen as it did not exhibit any cytotoxic effects as opposed to 40 µM. As shown in Figure 4 , treatments with PF543 and ABC294640 alone were 20 ± 9% and 12 ± 7%, respectively. In contrast, the combined treatment with PF543 and ABC294640 resulted in a 32 ± 6% decrease in cell index, demonstrating an additive effect. There was no evidence that any of these treatments exhibited any long-term cytotoxicity (Supplementary Figure 3) .
SK-1/2 inhibitors have varying effects on HUVEC barrier integrity
Whilst initially considered to be an exclusive inhibitor of SK-1, SKi has recently been demonstrated to inhibit both SK-1 and SK-2, with a K i of 16 µM and 7.9 µM respectively [18] . In contrast to both PF543 and ABC294640, SKi was unable to elicit a significant change in HUVEC barrier integrity at concentrations ranging from 5 μM to 40 μM ( Figure 5 ). There was
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no evidence of long-term cell toxicity following administration of SKi (Supplementary Figure 4) .
In addition to SKi, another SK-1/2 inhibitor, MP-A08, was also investigated in the in vitro HUVEC barrier integrity assay. MP-A08 exhibits a higher affinity for SK-2 than SK-1, with K i values of 6.9 µM and 27 µM respectively [56] . We administered MP-A08 at concentrations 
The SK inhibitors have varying effects on TrHBMEC barrier integrity
As variation is known to exist between ECs which are isolated from different vascular beds [3, 4] , we tested the response of the human bone marrow derived microvascular TrHBMEC cell line to the SK inhibitors. All inhibitors were examined at the optimal concentration as determined from the aforementioned HUVEC data: PF543 at 100 nM; ABC294640 at 20 µM; SKi at 40 µM; MP-A08 at 40 µM. Figure 7 shows that there was no evidence for changes in barrier integrity in response to treatment with either PF543 or SKi. In contrast, with ABC294640, a significant decrease in barrier integrity was observed, with a peak fall in cell index of 20 ± 5% ( Figure 7 ).
An even more pronounced effect on barrier integrity was observed with MP-A08, which caused a
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that only SKi had cytotoxic effects on the cells after approximately 6 hours in culture (Supplementary Figure 6 ).
Sphk1
-/-but not Sphk2 -/-mice have compromised microvascular barrier integrity
Intravital microscopy was used to compare the barrier integrity of the ear microvasculature of
Sphk1 -/-
, Sphk2 -/-mice and their WT counterparts in vivo. To note, our previous findings demonstrated that Sphk1 -/-mice have reduced microvascular barrier integrity in the back skin when using the Miles assay, which utilises Evans blue dye [37] but here we employed the much more sensitive approach of intravital microscopy. This technique allowed us to examine changes in permeability over time within live (anesthetised) mice using three different sizes of a FITCDextran tracer [14] . The largest molecule administered was a 150 kDa FITC-Dextran, which under basal conditions is reportedly too large to pass through the EC barrier [14] . Similarly, the 70 kDa FITC-Dextran is too large to pass through the vasculature under basal conditions, although some slight movement of the molecule into the interstitial space can be expected [14] .
The 40 kDa FITC-Dextran is small enough to move through the EC barrier under basal conditions and it is predicted to undergo a mild but sustained leakage over the course of the 15 minute imaging window [14] .
As shown in Figure 8 , with administration of the 150 kDa FITC-Dextran, the tracer is confined within the vasculature in the WT, Sphk1 -/-and Sphk2 -/-mice and undergoes little or no leakage into the interstitial space over the course of 15 minutes. There was no significant difference in the rate of leakage between these mice, which was assessed by determining the normalised total fluorescence area of each image at every time point ( Figure 8D ). Similarly, 
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9). Shown in Figure 9E , the differences in leakage of the 70 kDa FITC-Dextran tracers in the WT and Sphk1 -/-mice was not based on gender variation. A similar result was observed with the 40 kDa FITC-Dextran tracer, with the Sphk1 -/-mice exhibiting a significantly increased rate of leakage ( Figure 10 ). As anticipated, the 40 kDa FITC-Dextran tracer was still able to move into the interstitial space in the WT and Sphk2 -/-mice, although at a reduced rate compared to that observed in the Sphk1 -/-mice ( Figure 10 ). To note, we observed no differences in the proportion of small, medium or large diameter vessels across the different mouse strains for all sizes of FITC-Dextran examined (Supplementary Figure 7) . The only exception was within the small proportion of large vessels in the 70 kDa FITC-Dextran group, where a slight reduction in Sphk2 -/-numbers was detected (Supplementary Figure 7B) . However, this may be an artefact generated by the small sample size in this experiment. 
DISCUSSION
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this gene had no effect on EC barrier integrity while our data supported previous documentation of Sphk1 -/-mice having a compromised EC barrier [13, 37, 52, 75] .
The in vitro measurement of EC barrier integrity in this study was undertaken using an xCELLigence RTCA DP Analyzer, which employs electrical impedance-based technology to assess a range of cellular parameters. This technique was first described by Giaever and Keese [20, 21] , with the technology subsequently adapted for the xCELLigence platform [72] . The use of this methodology to assess changes in EC barrier integrity has been well-described and offers several advantages over the alternative transwell assay, including the ability to monitor changes in barrier integrity in real-time and without the use of a label [12, 31, 34, 35, 69, 76] . In order to establish whether this assay would be applicable to assessing the barrier integrity of our EC cultures, HUVEC were treated with the inflammatory mediator histamine, which is known to induce disruption of the EC barrier [41] . Our data indicated that histamine caused a rapid but transient decrease in HUVEC barrier integrity and that this effect was mediated by signaling through the histamine-1-receptor, which has been reported previously [62] . These findings validated the use of our HUVEC donor cultures and the xCELLigence RTCA DP Analyzer to assess EC barrier integrity in vitro.
To assess if SK-1 and SK-2 activity is important for the maintenance of EC barrier integrity in vitro, experiments using pharmacological inhibitors were undertaken. To inhibit SK-1 alone, PF543 was utilised, which is a sphingosine-competitive inhibitor that is 100-fold more selective for SK-1 than SK-2 and is described as the most potent inhibitor of SK-1 currently available [65] . We observed that PF543 caused a relatively small but significant decrease in barrier integrity at concentrations ranging from 10 nM to 100 nM. To-date, this is the only description of PF543 being used in this capacity. Inhibition of SK-2 was undertaken using the compound ABC294640, which acts as a competitive inhibitor with respect to sphingosine and exhibits strong selectivity towards SK-2 [17] . Our data indicated that treatment with ABC294640
caused a significant, but transient, reduction in HUVEC barrier integrity that was quantitatively larger than that seen with the SK-1 inhibitor PF-543. When both these inhibitors were combined, there was compelling evidence of an additive effect, further illustrating how both SK isoforms play an important role in the maintenance of EC barrier integrity.
In addition to PF543 and ABC294640, which preferentially inhibit specific SK isoforms, we utilised two compounds that have activity against both SK-1 and SK-2. SKi (also referred to as SKI-II), is a sphingosine-competitive inhibitor of both SK-1 and SK2 [15, 18] . There was no evidence from our data that SKi (5-40 µM) had any effect on EC barrier integrity, which is supported by Itagaki et al, who observed that SKi did not alter basal HUVEC barrier integrity in vitro using a transwell assay [27] . Along with SKi, we also utilised MP-A08, a recently developed inhibitor of both SK-1 and SK-2 [56] . As with ABC294640, the significant reduction in EC barrier integrity seen with MP-A08 treatment at 40 µM was larger than that observed with
PF543. Given that MP-A08 preferentially targets SK-2 [56], this supports our findings that pharmacological inhibition of SK-2 causes a disruption of EC barrier integrity in vitro.
Importantly, our previous data demonstrating that HUVEC possess comparable levels of SK-1 and SK-2 activity [73], suggest that the observed preferential role for SK-2 is not simply a result of predominance of this isoform in these cells.
Given the significant phenotypic heterogeneity that exists between different EC types isolated from different vascular beds [3, 4] , we also evaluated the response of the microvascular TrHBMEC line to the SK inhibitors. Characterization of the TrHBMEC demonstrates that they exhibit the classical hallmarks of ECs, including expression of von Willebrand factor, P-selectin and CD31 and up-take of acetylated low-density lipoprotein [66] . Both ABC294640 and MP-A08 induced a significant reduction in barrier integrity that was reminiscent of the data obtained from the HUVEC. Furthermore, SKi did not have any impact on barrier integrity, which was also in accordance with what was observed in HUVEC. In contrast to the HUVEC results however,
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This article is protected by copyright. All rights reserved. ] and (ii) the increased barrier integrity by angiopoietin-1 [37] . Whether the SK inhibitors had an effect independent of thrombin or angiopoietin-1 in these experiments was not
shown. Taken together, there is increasing evidence for an important and complex role for SK in the integrity of the vasculature that is yet to be clearly defined.
In recent years, there has been widespread interest in the use of SK inhibitors as therapeutics for a variety of conditions, most notably cancer (reviewed in [55] ). Many inhibitors are currently being evaluated in pre-clinical or clinical trials, with the structural sphingosine analogue FTY720 (also known as fingolimod and Gilenya TM ) approved for use as a treatment for multiple sclerosis [70] . Of the inhibitors used in this study, ABC294640 is currently undergoing a phase I/IIa clinical trial for the treatment of patients with diffuse large B cell lymphoma and has also shown potential as a therapeutic for prostate cancer [78] , whilst SKi and MP-A08 have documented anti-cancer properties [16, 56] . Interestingly, a relatively new class of anti-cancer drugs termed vascular-disrupting agents act by inducing increased vascular permeability within a tumor, thus restricting blood flow and the delivery of nutrients [77] . Given the permeabilityinducing properties of the SK inhibitors investigated here, it is possible that this mode-of-action might improve the efficacy of these agents as anti-tumor compounds. However, as tumor
vasculature is notoriously tortuous and leaky whether these agents further influence EC barrier integrity in this context remains to be determined. In addition, any possible side-effects that could result from increased vascular permeability must also be considered, including the potential for complications associated with edema [2] .
Previous studies have demonstrated that SK-1 activity is important for EC barrier integrity in vivo, with Sphk1 -/-mice exhibiting a higher propensity for microvascular leakage under both basal and inflammatory states [13, 37, 52, 75] . However, in contrast to the work undertaken here, none of these studies employed fluorescence-based intravital microscopy to assess microvascular integrity. transport of S1P out of the bloodstream and into the lymph circulation in Sphk2 -/-mice is responsible for the elevated plasma S1P [67] , although increases in SK-1 activity or decreases in S1P lyase or lipid phosphate phosphatase activity could also play a role. Given that S1P is a key mediator of EC barrier integrity [5, 7, 11, 40, 46] , it is likely that the reduced levels of S1P in the
Sphk1
-/-mice are responsible for the increased leakage of the FITC-Dextran tracer seen in these animals. The elevated plasma S1P found in Sphk2 -/-mice would also explain the normal EC barrier integrity we found in this study. Despite increases in S1P having been shown to mediate higher VEGF expression in ECs in vitro [25] , the subsequent increase in microvascular permeability that would result from VEGF secretion was not observed here.
It is evident from our data that a discrepancy exists between the SK-2 results from the in vitro and in vivo experiments. It is conceivable that the in vitro inhibitor data represents an intracellular mechanism of SK-1 and SK-2 action or the S1P they generate, as the effects of inhibitor addition are immediate (i.e. within seconds). With respect to SK-2, treatment of HUVEC with ABC294640 and MP-A08 could potentially reduce the level of secreted S1P, which would in turn decrease signaling through S1P 1 . However, it is possible that this mechanism does not account for all the changes in EC barrier integrity observed within our study. Intracellular targets of S1P have been identified and include histone deacetylases [22] , tumor necrosis factor receptor-associated factor 2 [8] , prohibitin-2 [71] , peroxisome proliferator activated receptor-γ [54] and possibly p-21 activated kinase 1 [42] . If S1P directly interacts with an intracellular pathway that regulates adhesion molecule interactions, then disruption of this pathway via inhibition of SK-2 could potentially weaken cell-cell contacts. In addition, given that SK-2 localises to organelles independently of SK-1, such as the nucleus, mitochondria and
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endoplasmic reticulum, S1P produced at these sites is likely to act on targets in close proximity and not be secreted from the cell [68] . In contrast to this proposed intracellular mode of action, findings from the Sphk2 -/-mouse are likely the result of elevated levels of S1P-induced S1P 1 mediated signaling [5, 7, 11, 39] , the effects of which may override any deficit in intracellular SK-2. It is also conceivable that some of the disparity seen between the in vitro and in vivo data could represent species differences in the regulation of EC barrier integrity by the sphingolipid pathway, although this would require further investigation.
In summary, our findings reveal a role for SK-2, via pharmacological manipulation, in the regulation of EC barrier integrity. Through use of the inhibitors ABC294640 and MP-A08, we
were able to present for the first time in vitro data showing a potential link between SK-2 activity and HUVEC and TrHBMEC barrier integrity. In addition, our study was able to confirm a role 
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